MILLENNIUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
Clinical Trials
457
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (372 trials with phase data)• Click on a phase to view related trials
An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT04535557
Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: TAK-906 Oral CapsuleDrug: [14C]-TAK-906 Intravenous InfusionDrug: [14C]-TAK-906 Oral Solution
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04454918
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04121078
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04091438
- Locations
- 🇺🇸
Wright Clinical Research, Alabaster, Alabama, United States
🇺🇸Pulmonary Associates Clinical Trials, Glendale, Arizona, United States
🇺🇸Preferred Research Partners, Inc., Little Rock, Arkansas, United States
Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04091425
- Locations
- 🇺🇸
Wright Clinical Research, Alabaster, Alabama, United States
🇺🇸Pulmonary Associates Clinical Trials, Glendale, Arizona, United States
🇺🇸Preferred Research Partners, Inc., Little Rock, Arkansas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 36
- Next
News
Patient-Caregiver Preferences Study Reveals Key Treatment Decision Factors in ALK+ NSCLC
A discrete choice experiment with 205 ALK+ NSCLC patients and 125 caregivers found that both groups overwhelmingly prioritized 3-year progression-free survival when making treatment decisions.
Novel Treatment Regimen Extends Myeloma Remission by Seven Months in UK Clinical Trial
A phase 3 clinical trial led by the University of Leeds demonstrated that a second stem cell transplant followed by ixazomib maintenance therapy extends myeloma remission by seven months compared to standard care.
Triplet Therapy Shows Promise in Advanced Chronic Myeloid Leukemia
A novel triplet regimen of decitabine, venetoclax, and ponatinib achieved bone marrow remission in 80% of advanced-phase CML patients.